Fintel reports that on January 7, 2025, Jefferies upgraded their outlook for Instil Bio (NasdaqCM:TIL) from Hold to Buy.
Analyst Price Forecast Suggests 402.90% Upside
As of December 24, 2024, the average one-year price target for Instil Bio is $102.34/share. The forecasts range from a low of $11.11 to a high of $189.00. The average price target represents an increase of 402.90% from its latest reported closing price of $20.35 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Instil Bio is 2MM, an increase of ∞%. The projected annual non-GAAP EPS is -1.33.
What is the Fund Sentiment?
There are 83 funds or institutions reporting positions in Instil Bio. This is an increase of 33 owner(s) or 66.00% in the last quarter. Average portfolio weight of all funds dedicated to TIL is 0.66%, an increase of 129.89%. Total shares owned by institutions increased in the last three months by 29.32% to 5,532K shares.
What are Other Shareholders Doing?
Curative Ventures V holds 1,899K shares representing 29.10% ownership of the company. No change in the last quarter.
Vivo Capital holds 624K shares representing 9.57% ownership of the company. No change in the last quarter.
CPMG holds 411K shares representing 6.30% ownership of the company. No change in the last quarter.
Boxer Capital holds 356K shares representing 5.45% ownership of the company.
Perceptive Advisors holds 346K shares representing 5.29% ownership of the company.
Instil Bio Background Information
(This description is provided by the company.)
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
